Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Significant predictors of pathological response include HER2 protein overexpression by IHC, grade 3 histology, PR-negative status, and dual anti-HER2 therapy. Additional studies are needed to ...

Most of the literature reports a correlation between HER-2 overexpression and increased sensitivity to anthracycline-based chemotherapy in comparison with CMF and tamoxifen (Elledge et al ...

Learn about HER2-positive breast cancer, its symptoms, causes, and prevention tips. Understand early signs and available ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

On the other hand, the MyPathway study used any clear certified test that showed HER2 amplification or overexpression, similar to the MOUNTAINEER study, and they showed response rates of anywhere ...

This leads to too many HER2 proteins in your breast cells, a situation called "protein overexpression." The result is breast cells that divide and grow too quickly. Special tests help your doctor ...

Kanwal Raghav, MD, MBBS: Uptake of HER2-targeted therapy in metastatic colorectal cancer is evolving, and it’s increasingly becoming better. Most of the trials that we’re talking about are 4 ...

HER2 classification relies on immunohistochemistry ... HER2 assays are semiquantitative and were optimized to detect HER2 overexpression. Furthermore, some data suggest that IHC 0 cancers respond ...

HER2 overexpression or amplification is a known poor prognostic indicator in various malignancies and has been previously studied in EMPD, albeit with limited sample sizes. The rates of HER2 ...

Breast cancers that arise in patients aged younger than 40 years are more likely to have aggressive disease biology, including HER2 overexpression. It is estimated that 25% or more of young ...